0001415889-19-000248.txt : 20190305
0001415889-19-000248.hdr.sgml : 20190305
20190305160520
ACCESSION NUMBER: 0001415889-19-000248
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20190301
FILED AS OF DATE: 20190305
DATE AS OF CHANGE: 20190305
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: AHMED NADIM
CENTRAL INDEX KEY: 0001731193
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-34912
FILM NUMBER: 19658273
MAIL ADDRESS:
STREET 1: C/O CELGENE CORPORATION
STREET 2: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: CELGENE CORP /DE/
CENTRAL INDEX KEY: 0000816284
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 222711928
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
BUSINESS PHONE: (908)673-9000
MAIL ADDRESS:
STREET 1: 86 MORRIS AVENUE
CITY: SUMMIT
STATE: NJ
ZIP: 07901
4
1
form4-03052019_040307.xml
X0306
4
2019-03-01
0000816284
CELGENE CORP /DE/
CELG
0001731193
AHMED NADIM
C/O CELGENE CORPORATION
86 MORRIS AVENUE
SUMMIT
NJ
07901
false
true
false
false
PRES., HEMATOLOGY AND ONCOLOGY
Restricted Stock Unit
2019-03-01
4
A
0
27749
0
A
Common Stock
27749
27749
D
Each restricted stock unit represents a contingent right to receive one share of the Company's common stock.
The restricted stock units will vest in three equal annual installments, beginning on March 1, 2020. Vested shares will be delivered to the reporting person promptly after the vesting date.
The restricted stock units were issued pursuant to the Company's 2017 Stock Incentive Plan.
President, Inflammation and Immunology
/s/ Mark J. Alles, Attorney-in-Fact
2019-03-05